文献速递淋巴瘤

滤泡性淋巴瘤24个月内进展与瘤内免疫浸润减少相关

Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.
PubMed 文献 · J Clin Oncol · 2019-08-28

该研究探讨滤泡性淋巴瘤(FL)患者24个月内进展(POD24)与瘤内免疫浸润的关系。通过数字基因表达分析发现,低PD-L2表达可区分免疫浸润低(免疫浸润LO)与高(免疫浸润HI)的肿瘤,免疫浸润LO患者POD24事件显著富集,并在两个独立队列中验证。结论认为PD-L2表达评估有助于识别POD24风险患者。

要点

  • 低PD-L2表达是区分FL免疫浸润高低的最敏感/特异标志物。
  • 免疫浸润LO的FL患者POD24事件显著富集(OR=4.32)。
  • PD-L2表达评估有助于识别POD24高风险患者。

核心结论

  • 通过PD-L2表达评估免疫浸润是识别POD24风险患者的有前景工具。

研究设计与样本

  • 发现队列纳入早期和晚期FL患者132例,进行数字基因表达、T细胞受体库分析、流式细胞术、多光谱免疫荧光和二代测序。
  • 验证队列包括两个独立晚期FL患者队列:接受R-CVP方案者138例,接受R-CHOP方案者45例(后者用于比较POD24患者与5年以上无进展患者)。

主要发现

  • 免疫分子呈现高或低表达的 distinct 聚类,低PD-L2是区分不良结局患者最敏感/特异的标志物。
  • 免疫浸润HI组织富含巨噬细胞和扩增的T细胞克隆。
  • 突变在免疫浸润HI和LO组织中分布均等,表明免疫浸润程度反映的FL生物学特征独立于突变谱。

临床怎么用

  • 可通过检测PD-L2表达评估瘤内免疫浸润水平,辅助识别POD24高风险FL患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Understanding the immunobiology of the 15% to 30% of patients with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) remains a priority. Solid tumors with low levels of intratumoral immune infiltration have inferior outcomes. It is unknown whether a similar relationship exists between POD24 in FL. PATIENTS AND METHODS: Digital gene expression using a custom code set-five immune effector, six immune checkpoint, one macrophage molecules-was applied to a discovery cohort of patients with early- and advanced-stage FL (n = 132). T-cell receptor repertoire analysis, flow cytometry, multispectral immunofluorescence, and next-generation sequencing were performed. The immune infiltration profile was validated in two independent cohorts of patients with advanced-stage FL requiring systemic treatment (n = 138, rituximab plus cyclophosphamide, vincristine, prednisone; n = 45, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), with the latter selected to permit comparison of patients experiencing a POD24 event with those having no progression at 5 years or more. RESULTS: Immune molecules showed distinct clustering, characterized by either high or low expression regardless of categorization as an immune effector, immune checkpoint, or macrophage molecule. Low programmed death-ligand 2 (PD-L2) was the most sensitive/specific marker to segregate patients with adverse outcomes; therefore, PD-L2 expression was chosen to distinguish immune infiltrationHI (ie, high PD-L2) FL biopsies from immune infiltrationLO (ie, low PD-L2) tumors. Immune infiltrationHI tissues were highly infiltrated with macrophages and expanded populations of T-cell clones. Of note, the immune infiltrationLO subset of patients with FL was enriched for POD24 events (odds ratio [OR], 4.32; c-statistic, 0.81; P = .001), validated in the independent cohorts (rituximab plus cyclophosphamide, vincristine, prednisone: OR, 2.95; c-statistic, 0.75; P = .011; and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone: OR, 7.09; c-statistic, 0.88; P = .011). Mutations were equally proportioned across tissues, which indicated that degree of immune infiltration is capturing aspects of FL biology distinct from its mutational profile. CONCLUSION: Assessment of immune-infiltration by PD-L2 expression is a promising tool with which to help identify patients who are at risk for POD24.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tobin JWD, Keane C, Gunawardana J, et al. Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration. J Clin Oncol. 2019. PMID: 31461379. doi:10.1200/JCO.18.02365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。